This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Scheinfeldt LB , Brangan A , Kusic DM , Kumar S , Gharani N
Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants
J Pers Med. 2021 Feb 16;11(2)
PMID: 33669176 PMCID: PMC7919641 URL: https://www.ncbi.nlm.nih.gov/pubmed/33669176
AbstractPharmacogenomics holds the promise of personalized drug efficacy optimization and drug toxicity minimization. Much of the research conducted to date, however, suffers from an ascertainment bias towards European participants. Here, we leverage publicly available, whole genome sequencing data collected from global populations, evolutionary characteristics, and annotated protein features to construct a new in silico machine learning pharmacogenetic identification method called XGB-PGX. When applied to pharmacogenetic data, XGB-PGX outperformed all existing prediction methods and identified over 2000 new pharmacogenetic variants. While there are modest pharmacogenetic allele frequency distribution differences across global population samples, the most striking distinction is between the relatively rare putatively neutral pharmacogene variants and the relatively common established and newly predicted functional pharamacogenetic variants. Our findings therefore support a focus on individual patient pharmacogenetic testing rather than on clinical presumptions about patient race, ethnicity, or ancestral geographic residence. We further encourage more attention be given to the impact of common variation on drug response and propose a new 'common treatment, common variant' perspective for pharmacogenetic prediction that is distinct from the types of variation that underlie complex and Mendelian disease. XGB-PGX has identified many new pharmacovariants that are present across all global communities; however, communities that have been underrepresented in genomic research are likely to benefit the most from XGB-PGX's in silico predictions.
Notes2075-4426 Scheinfeldt, Laura B Orcid: 0000-0001-6529-6701 Brangan, Andrew Kusic, Dara M Kumar, Sudhir Orcid: 0000-0002-9918-8212 Gharani, Neda R01 LM013385/LM/NLM NIH HHS/United States R35 GM139540/GM/NIGMS NIH HHS/United States U41 HG008736/HG/NHGRI NIH HHS/United States Journal Article J Pers Med. 2021 Feb 16;11(2):131. doi: 10.3390/jpm11020131.